Amgen Drops Repatha List Price 60% To Cut Medicare Co-Pays And Boost Use
Company says 75% of Medicare Part D patients who aren't eligible for low income subsidies abandon the PCSK9 inhibitor at the pharmacy counter due to $370 co-pay, which may now range from $25-$150 per dose.
You may also be interested in...
On eve of congressional hearing, the pharmacy benefit manager assures Amgen that Repatha is available to its employees.
Recent launches by Lilly, Amgen and Gilead suggest list prices may decrease with the HHS proposal to disrupt the rebate system, but not as low as current net prices after rebates, according to pharmacy benefit experts.
Program likely to generate fewer rebates so it remains to be seen whether payers will embrace the new model in a big way.